{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:07:46Z","timestamp":1789826866431,"version":"4.0.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.semarthrit.2023.152191","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T12:19:13Z","timestamp":1678882753000},"page":"152191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-663X","authenticated-orcid":false,"given":"Melanie B.","family":"Morillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"N\u00f8rup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe Mette","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Diaz-Torne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lawrence","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkell J.","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0138-2912","authenticated-orcid":false,"given":"Lisa K.","family":"Stamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152191_bib0001","unstructured":"Dorcas E, Beaton, SG, Lara J Maxwell, Beverley J Shea, Peter Tugwell. Chapter 1. OMERACT handbook. 2021;https:\/\/omeracthandbook.org\/handbook:1-8."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0002","unstructured":"OMERACT website (www.omeract.org)."},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0003","doi-asserted-by":"crossref","first-page":"e99111","DOI":"10.1371\/journal.pone.0099111","article-title":"Choosing important health outcomes for comparative effectiveness research: a systematic review","volume":"6","author":"Gargon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0004","unstructured":"Williamson P, Fau - Altman D, Altman D, Fau - Blazeby J, Blazeby J, Fau - Clarke M, Clarke M, Fau - Gargon E, Gargon E. Driving up the quality and relevance of research through the use of agreed core outcomes. (1758-1060 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0005","series-title":"The OMERACT Handbook 2021","article-title":"Developing core domain sets","author":"Beaton","year":"2021"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152191_bib0006","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.181096","article-title":"OMERACT filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies","volume":"46","author":"Boers","year":"2019","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152191_bib0007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jclinepi.2013.11.013","article-title":"Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0","volume":"67","author":"Boers","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0008","first-page":"1381","article-title":"Outcome evaluations in gout","volume":"34","author":"Schumacher","year":"2007","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0009","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.2007.079970","article-title":"A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout","volume":"67","author":"Taylor","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152191_bib0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152191_bib0011","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.090371","article-title":"Progress in measurement instruments for acute and chronic gout studies","volume":"36","author":"Grainger","year":"2009","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152191_bib0012","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0013","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3899\/jrheum.131246","article-title":"OMERACT endorsement of measures of outcome for studies of acute gout","volume":"41","author":"Singh","year":"2014","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.23607","article-title":"Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout","volume":"71","author":"Bursill","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0015","unstructured":"Hughes KL, Clarke M, Williamson PR. A systematic review finds core outcome set uptake varies widely across different areas of health. (1878-5921 (Electronic))."},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0016","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3899\/jrheum.170911","article-title":"Variability in the reporting of serum urate and flares in gout clinical trials: need for minimum reporting requirements","volume":"45","author":"Stamp","year":"2017","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152191_bib0017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.semarthrit.2019.11.002","article-title":"How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials","volume":"50","author":"Stewart","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152191_bib0018","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0019","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3899\/jrheum.131246","article-title":"OMERACT endorsement of measures of outcome for studies of acute gout","volume":"41","author":"Singh","year":"2014","journal-title":"J Rheumatol"},{"issue":"372","key":"10.1016\/j.semarthrit.2023.152191_bib0020","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"29","author":"Page","year":"2021","journal-title":"BMJ (Clini Res ed)"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0021","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14728214.2018.1527899","article-title":"Expert opinion on emerging urate-lowering therapies","volume":"23","author":"Stamp","year":"2018","journal-title":"Expert Opin Emerging Drugs"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0022","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.berh.2019.03.010","article-title":"Management of complex gout in clinical practice: Update on therapeutic approaches","volume":"32","author":"Narang","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0024","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/rheumatology\/keu424","article-title":"Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review","volume":"54","author":"Araujo","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0025","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"60","key":"10.1016\/j.semarthrit.2023.152191_bib0027","first-page":"239","article-title":"Ultrasound for the diagnosis of gout-the value of gout lesions as defined by the Outcome Measures in Rheumatology ultrasound group","volume":"5","author":"\u00d8M","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0028","unstructured":"Kirkham JJ, Boers M, Fau - Tugwell P, Tugwell P, Fau - Clarke M, Clarke M, Fau - Williamson PR, Williamson PR. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. (1745-6215 (Electronic))."},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0029","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0030","first-page":"275","article-title":"A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout","volume":"10","author":"Douglas","year":"1970","journal-title":"Ann Phys Med"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0031","unstructured":"Smyth Cj Fau - Percy JS, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. (0003-4967 (Print))."},{"issue":"21","key":"10.1016\/j.semarthrit.2023.152191_bib0032","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009747809095668","article-title":"Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial","author":"Ruotsi","year":"1978","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0033","unstructured":"Weiner Gi, Fau - White SR, White Sr Fau - Weitzner RI, Weitzner Ri, Fau - Rubinstein HM, Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. (0004-3591 (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0034","unstructured":"Reardon Ja, Fau - Stockman A, Stockman A, Fau - Darlington LG, Darlington Lg, Fau - Scott JT, Scott JT. Double-blind trial of feprazone and phenylbutazone in acute gout. (0300-7995 (Print))."},{"issue":"4a","key":"10.1016\/j.semarthrit.2023.152191_bib0035","first-page":"641","article-title":"Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study","volume":"33","author":"Eberl","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0036","unstructured":"Butler Rc, Fau - Goddard DH, Goddard Dh, Fau - Higgens CS, Higgens Cs, Fau - Hollingworth P, et\u00a0al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. (0306-5251 (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0037","unstructured":"Tumrasvin T, Fau - Deesomchok U, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. (0125-2208 (Print))."},{"issue":"3a","key":"10.1016\/j.semarthrit.2023.152191_bib0038","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(86)90131-2","article-title":"Flurbiprofen in the treatment of acute gout. A comparison with indomethacin","volume":"80","author":"Lomen","year":"1986","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0039","unstructured":"Ahern MJ, Reid C, Fau - Gordon TP, Gordon Tp, Fau - McCredie M, McCredie M, Fau - Brooks PM, Brooks Pm, Fau - Jones M, Jones M. Does colchicine work? The results of the first controlled study in acute gout. (0004-8291 (Print))."},{"issue":"302","key":"10.1016\/j.semarthrit.2023.152191_bib0040","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia","volume":"37","author":"Fraser","year":"1987","journal-title":"J R Coll Gen Pract"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0041","unstructured":"Altman RD, Honig S, Fau - Levin JM, Levin Jm, Fau - Lightfoot RW, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. (0315-162X (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0042","unstructured":"Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. (0004-3591 (Print))."},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0043","first-page":"344","article-title":"A double-blind comparison of Etodolac (Lodine\u00ae) and high doses of naproxen in the treatment of acute gout","volume":"7","year":"1990","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152191_bib0044","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0045","unstructured":"Alloway JA, Moriarty Mj, Fau - Hoogland YT, Hoogland Yt, Fau - Nashel DJ, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. (0315-162X (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0046","unstructured":"Shrestha M, Morgan Dl, Fau - Moreden JM, Moreden Jm, Fau - Singh R, Singh R, Fau - Nelson M, Nelson M, Fau - Hayes JE, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. (0196-0644 (Print))."},{"issue":"7352","key":"10.1016\/j.semarthrit.2023.152191_bib0047","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152191_bib0048","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152191_bib0049","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0149-2918(04)90035-5","article-title":"A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0050","doi-asserted-by":"crossref","unstructured":"Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. May 2007;49(5):670-7. doi:10.1016\/j.annemergmed.2006.11.014.","DOI":"10.1016\/j.annemergmed.2006.11.014"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0051","unstructured":"Willburger RE, Mysler E Fau - Derbot J, Derbot J Fau - Jung T, et\u00a0al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. (1462-0324 (Print))."},{"issue":"9627","key":"10.1016\/j.semarthrit.2023.152191_bib0052","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0053","unstructured":"Terkeltaub RA, Furst De, Fau - Bennett K, Bennett K, Fau - Kook KA, Kook Ka, Fau - Crockett RS, Crockett Rs, Fau - Davis MW, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. (1529-0131 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0054","unstructured":"So A, De Meulemeester M Fau - Pikhlak A, Pikhlak A Fau - Y\u00fccel AE, et\u00a0al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. (1529-0131 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0055","unstructured":"Schlesinger N, De Meulemeester M Fau - Pikhlak A, Pikhlak A Fau - Y\u00fccel AE, et\u00a0al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. (1478-6362 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0056","unstructured":"Schlesinger N, Alten Re, Fau - Bardin T, Bardin T, Fau - Schumacher HR, et\u00a0al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. (1468-2060 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0057","unstructured":"Schumacher HR, Berger Mf, Fau - Li-Yu J, Li-Yu J, Fau - Perez-Ruiz F, Perez-Ruiz F, Fau - Burgos-Vargas R, Burgos-Vargas R, Fau - Li C, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. 32. (0315-162X (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0058","unstructured":"Li T, Chen Sl, Fau - Dai Q, Dai Q, Fau - Han X-H, et\u00a0al. Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial. (2542-5641 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0059","unstructured":"Schumacher HR, Jr., Sundy Js, Fau - Terkeltaub R, Terkeltaub R, Fau - Knapp HR, et\u00a0al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. (1529-0131 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0060","unstructured":"Zhang YK, Yang H, Fau - Zhang JY, Zhang Jy, Fau - Song LJ, Song Lj, Fau - Fan YC, Fan YC. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. (1742-1241 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0061","unstructured":"Rainer Th, Fau - Cheng CH, Cheng Ch, Fau - Janssens HJEM, Janssens Hj, Fau - Man CY, et\u00a0al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, Random Trial. (1539-3704 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0062","doi-asserted-by":"crossref","first-page":"810","DOI":"10.12659\/MSM.895749","article-title":"Comparison of prednisolone, etoricoxib, and indomethacin in treatment of acute gouty arthritis: an open-label, randomized, controlled trial","volume":"22","author":"Xu","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0063","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","author":"Janssen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0064","article-title":"Naproxen or low-dose colchicine for gout flares in primary care? Response to: 'Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care' by Parperis et\u00a0al","author":"Roddy","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0065","unstructured":"Ren S, Meng F, Liu Y, et\u00a0al. Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: a randomized controlled trial. (1749-8546 (Print))."},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0066","first-page":"623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0067","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.41.1.59","article-title":"Allopurinol treatment and its effect on renal function in gout: a controlled study","volume":"41","author":"Gibson","year":"1982","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0068","first-page":"21","article-title":"Effects of allopurinol and benzbromarone on renal clearance of creatinine and uric acid in gouty patients","volume":"3","year":"1991","journal-title":"Japan J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0069","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"M\u00fcller","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152191_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol: Pract Rep Rheumat Musculoskel Dis"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0071","unstructured":"Becker MA, Schumacher Hr Jr, Fau - Wortmann RL, Wortmann Rl, Fau - MacDonald PA, et\u00a0al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. (0004-3591 (Print))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0072","unstructured":"Becker MA, Schumacher Hr Jr, Fau - Wortmann RL, Wortmann Rl, Fau - MacDonald PA, et\u00a0al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. (1533-4406 (Electronic))."},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152191_bib0073","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0074","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0076","unstructured":"Becker MA, Schumacher Hr, Fau - Espinoza LR, Espinoza Lr, Fau - Wells AF, et\u00a0al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. (1478-6362 (Electronic))."},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152191_bib0077","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0078","unstructured":"Taylor TH, Mecchella Jn, Fau - Larson RJ, Larson Rj, Fau - Kerin KD, Kerin Kd, Fau - Mackenzie TA, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. (1555-7162 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0079","unstructured":"Huang X, Du H Fau - Gu J, Gu J Fau - Zhao D, et\u00a0al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. (1756-185X (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0080","unstructured":"Hill EM, Sky K Fau - Sit M, Sit M Fau - Collamer A, Collamer A Fau - Higgs J, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. (1536-7355 (Electronic))."},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0081","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0082","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheumat Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152191_bib0083","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0084","unstructured":"Bardin T, Keenan RT, Khanna PP, et\u00a0al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). (1468-2060 (Electronic))."},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152191_bib0085","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152191_bib0086","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152191_bib0087","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0088","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152191_bib0089","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152191_bib0090","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/14397595.2018.1538003","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials","volume":"29","author":"Fitz-Patrick","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0091","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","article-title":"Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study","volume":"20","author":"Gunawardhana","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0092","unstructured":"Kankam M, Hall J, Gillen M, et\u00a0al. Pharmacokinetics, pharmacodynamics, and tolerability of concomitant multiple dose administration of Verinurad (RDEA3170) and allopurinol in adult male subjects with gout. (1552-4604 (Electronic))."},{"key":"10.1016\/j.semarthrit.2023.152191_bib0093","first-page":"1623","article-title":"The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia","volume":"31","author":"Wang","year":"2018","journal-title":"Pak J Pharm Sci"},{"issue":"13","key":"10.1016\/j.semarthrit.2023.152191_bib0094","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0095","unstructured":"Yamanaka H, Tamaki S, Ide Y, et\u00a0al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. (1468-2060 (Electronic))."},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0096","first-page":"812","article-title":"Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-\u03b1 and COX-2","volume":"17","author":"Hao","year":"2019","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0097","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","article-title":"Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort","volume":"21","author":"Liang","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152191_bib0098","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","article-title":"Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152191_bib0099","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520902950","article-title":"The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout","volume":"48","author":"Huang","year":"2020","journal-title":"J Int Med Res"},{"key":"10.1016\/j.semarthrit.2023.152191_bib0100","unstructured":"Mackenzie IS, Ford I, Nuki G, et\u00a0al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. (1474-547X (Electronic))."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:10:52Z","timestamp":1758733852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":100,"alternative-id":["S0049017223000318"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152191","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome reporting in randomized trials in gout: A systematic scoping review from the OMERACT gout working group assessing the uptake of the core outcome set","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152191"}}